证券代码：688246 证券简称：嘉和美康 嘉和美康（北京）科技股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 3 月 27 日 | 2025 | 年第二次临时股东大会会议须知 2 | | --- | --- | | 2025 | 年第二次临时股东大会会议议程 4 | | 2025 | 年第二次临时股东大会会议议案 6 | | 议案一：关于公司 | 2025 年度日常关联交易预计的议案 6 | | 议案二：关于公司 | 2025 年度对外担保预计的议案 8 | 目 录 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《公司章程》《股东大会议事规则》等相关规定，特 制定嘉和美康（北京）科技股份有限公司（以下简称"公司"）2025 年第二次 临时股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实 ...

Investment Rating - The report assigns a "Buy" rating for the stocks of Weining Health, Chuangye Huikang, and Jiahe Meikang, indicating an expectation of strong performance in the next 12 months [5][50]. Core Insights - The medical IT industry is experiencing a recovery in orders, with a notable increase in AI-related orders expected in the future [4][45]. - The total order amount for the medical IT industry in January-February 2025 was 767 million CNY, a decrease of 7.9% compared to the same period in 2024, while the number of orders increased by 5.2% [4][42]. - The structure of orders shows that traditional hospital information projects account for 91.2% of the total, indicating a strong demand in this area due to regulatory pressures for system upgrades [4][43]. Summary by Sections 1. Overview of Medical IT Industry Orders - The report analyzes data from 11 A-share listed medical information companies, highlighting a recovery trend in orders for February 2025 [4][12]. - The cumulative order amount for January-February 2025 was 767 million CNY, slightly down from 833 million CNY in the same period last year, while the number of orders rose to 448 from 426 [4][13][42]. 2. Monthly Order Data - In February 2025, the medical IT industry recorded an order amount of 340 million CNY, a year-on-year increase of 15.9%, with 174 orders, up 30.8% year-on-year [4][18][42]. 3. Order Structure - Traditional hospital information projects dominate the order structure, with 91.2% of total orders, followed by electronic medical records at 6.8% and medical insurance IT at 2.1% [4][39][43]. 4. Supplier Landscape - In February 2025, the leading suppliers for million-level orders were Jiahe Meikang (35.2%), Donghua Software (34.2%), and Weining Health (23.5%), indicating a high market concentration [4][33][36]. - The report suggests that leading companies will have a greater advantage in securing large orders due to stricter regulations and a more standardized bidding process [4][36][44]. 5. Investment Recommendations - The report anticipates a sustained increase in medical IT demand over the next 3-5 years, particularly with the integration of AI technologies [4][45]. - Companies such as Weining Health, Chuangye Huikang, and Jiahe Meikang are highlighted as having significant advantages, along with a recommendation to monitor AI-related medical companies [4][45].

证券代码：688246 证券简称：嘉和美康 公告编号：2025-018 嘉和美康（北京）科技股份有限公司 关于公司2025年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●是否需要提交股东大会审议：是。 本次2025年度日常关联交易预计额度达到公司最近一期经审计总资产或市 值1%以上，且超过3,000万元，根据《上海证券交易所科创板股票上市规则》（以 下简称"《上市规则》"）7.2.4条规定，本议案尚需提交公司股东大会审议，相关 关联股东将回避表决。 （二）本次日常关联交易预计金额和类别 根据《上市规则》及相关法律法规，公司预计2025年日常关联交易额度，具 体如下： 关联交易 类别 关联方 2025 年 度预计 金额 占同类 业务比 例 本年年 初至披 露日与 关联人 累计已 发生的 交易金 额 2024 年度 实际 发生 金额 占同 类业 务比 例 本次预计 金额与 2024 年实 际发生金 额差异较 大的原因 向关联方 销售产 品、商品 或提供劳 务 北京安德医 智科技有限 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2025-019 嘉和美康（北京）科技股份有限公司 关于公司 2025 年度对外担保预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 被担保方：全资子公司北京嘉和美康信息技术有限公司（以下简称"嘉和 信息"）。 本次担保金额及已实际为其提供的担保余额：嘉和美康（北京）科技股 份有限公司（以下简称"公司"）预计 2025 年度为嘉和信息提供担保额度合计不 超过人民币 62,000 万元（含）。截至 2025 年 3 月 7 日，公司为嘉和信息提供的 担保余额为 31,976.08 万元。 被担保人是否提供反担保：否 本事项已经公司第四届董事会第二十四次会议审议通过，尚需提交 2025 年第二次临时股东大会进行审议。 一、担保情况概述 为满足公司日常生产经营与业务发展需求，保证其业务顺利开展，结合公司 2025 年度发展计划，嘉和信息拟向银行申请不超过人民币 62,000 万元的综合授 信额度，同时公司拟为嘉和信息申请的上述综合授信额度共计不超过人 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2025-020 嘉和美康（北京）科技股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025 年第二次临时股东大会 召开日期时间：2025 年 3 月 27 日 14 点 30 分 召开地点：北京市海淀区东北旺西路 8 号院 28 号楼 1 层会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 3 月 27 日 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公 ...

校对：彭其华 此外，2月25日，复旦大学附属中山医院联合上海科学智能研究院发布了全国首个AI心脏大模型"观 心"测试版。这一事件标志着AI技术在医疗领域的商业化应用迈出了重要一步，尤其是在心脏疾病这一 高发且治疗成本较高的领域。通过整合海量医疗数据和先进的深度学习算法，"观心"模型能够实现心脏 疾病的早期筛查、精准诊断和个性化治疗方案推荐，显著提升诊疗效率并降低医疗成本。 平安证券指出，从行业角度来看，AI医疗模型的商业化落地不仅为医疗机构提供了强有力的技术支 持，也为相关产业链带来了新的增长点。随着AI技术在医疗影像、病理分析、药物研发等领域的广泛 应用，医疗设备、数据服务和健康管理等细分市场有望迎来快速发展。此次"观心"模型的发布，进一步 验证了AI技术在医疗领域的商业化潜力，预计将吸引更多资本和技术投入。AI医疗领域的创新企业和 技术领先者值得重点关注，建议关注与AI医疗相关的龙头企业及技术创新公司，把握行业变革带来的 长期投资机遇。 AI医疗概念3日盘中再度活跃，截至发稿，嘉和美康、安必平涨超12%，启迪药业、贝瑞基因、润达医 疗、塞力医疗等涨停，金域医学涨超8%，华大基因涨近5%。 行业方面，2月2 ...

Financial Performance - The total revenue for 2024 was RMB 60,072.44 million, a decrease of 13.59% compared to the previous year[4] - The net profit attributable to the parent company was RMB -14,997.36 million, representing a decline of 452.90% year-on-year[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB -15,630.23 million, down 538.23% from the previous year[4] - The basic earnings per share were RMB -1.09, a decrease of 451.61% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 261,729.46 million, a decrease of 1.12% year-on-year[6] - The equity attributable to the parent company was RMB 167,426.82 million, down 8.77% from the previous year[6] Research and Development - The company maintained high R&D investment, focusing on AI technology exploration and product iteration, with plans to release a new version of the intelligent electronic medical record platform in early 2025[11] Investment and Losses - The company faced significant losses from its associate company, Beijing Ande Medical Technology Co., Ltd., which impacted the investment loss recognized by the company[10] Revenue Decline Factors - The decline in revenue was attributed to delayed customer demand, prolonged bidding processes, and extended delivery cycles due to the overall economic and medical industry environment[7] - The company has increased its asset impairment provisions significantly due to the extended collection periods from hospital clients[9]

Summary of the Conference Call for 嘉和美康 Company Overview - 嘉和美康 is a leading company in the electronic medical record (EMR) system market, with a significant presence in big data platform products. The business is divided into three main segments: clinical (over 50% of revenue), medical data (25%-30%), and life sciences (6%-7%) [2][3][27]. Key Insights and Arguments - The company has invested in medical text AI since 2019, establishing 嘉和智能 and collaborating with 北医三院 to create an AI laboratory. They have developed a large medical model that has been validated in various surgical departments [2][4][5]. - 嘉和美康 has over 800 users of its EMR system in tertiary hospitals, providing a rich dataset for developing new models and enhancing smart diagnosis capabilities [2][6]. - The integration of a Clinical Decision Support System (CDSS) into the V7 version of the EMR is planned, focusing on critical care, dentistry, and emergency medicine to improve treatment outcomes while controlling costs [2][10][11]. - The adjustment of EMR ratings to smart medical ratings emphasizes AI applications and data integration, aligning well with 嘉和美康's core business, potentially accelerating customer adoption [2][27]. - The policy to increase and renovate critical care beds is significant for the company, as it sells systems based on bed count, with each bed priced at approximately 40,000 to 60,000 yuan [2][28]. Industry Dynamics - The exit of smaller firms from the market due to financial constraints benefits 嘉和美康 by increasing industry concentration [2][29]. - The overall penetration of EMR systems in hospitals has improved since 2018, but the level of intelligence remains low, with many hospitals using external products like CDSS that lack deep learning capabilities [2][14]. - The company faces challenges in AI product acceptance due to high clinical thinking requirements and competition from well-resourced foundational model vendors [2][8][32]. Future Directions - 嘉和美康 aims to enhance its existing EMR platform by integrating AI applications and developing an integrated solution centered on clinical data to meet market demands for smart healthcare [2][9]. - The company plans to maintain its investment levels while shifting traditional product development resources towards AI [2][9]. - The future landscape of AI tools in hospitals is expected to involve collaborative platforms that integrate various specialties rather than standalone applications [2][39]. Additional Important Points - The company has made significant strides in AI, including the launch of the V7 EMR and the acquisition of 安德益智, which enhances its competitive edge in the healthcare information technology sector [2][30][31]. - The quality of data is crucial for training clinical models, and 嘉和美康 emphasizes the need for high-quality, standardized data [2][16][17]. - The willingness of hospitals to pay for specialized software depends on the tangible benefits it provides, such as improved research capabilities and performance evaluations [2][24][25]. This summary encapsulates the key points discussed during the conference call, highlighting 嘉和美康's strategic initiatives, market positioning, and future outlook in the healthcare technology sector.

证券代码：688246 证券简称：嘉和美康 公告编号：2025-016 嘉和美康（北京）科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （二）重大事项情况 ●截至 2025 年 2 月 17 日，公司收盘价为 39.90 元/股，根据中证指数有 限公司发布的数据，公司最新的静态市盈率为129.18倍、最新市净率为3.07倍， 公司所处的软件和信息技术服务业的最新静态市盈率为 67.73 倍、最新市净率为 5.06 倍。公司当前股价存在非理性炒作风险以及回调的可能，交易风险较大，公 司特别提醒广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 公司股票交易于 2025 年 2 月 14 日、2 月 17 日连续两个交易日内收盘价格 涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券交易所科 创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动的情形。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自 ...

1、截至目前,作为贵公司控股股东和实际控制人,不存在正在筹划并购重 组、股份发行、债务重组、业务重组、资产剥离和资产注入等重大事项，亦不 存在其他应披露而未披露的重大信息。 2、本人在贵公司本次股票异常波动期间，不存在买卖贵公司股票的情况。 控股股东/实际控制人: 2025年2月17日 《关于嘉和美康（北京）科技股份有限公司股票交 易异常波动的询证函》的回函 致:嘉和美康(北京)科技股份有限公司 贵公司《关于嘉和美康(北京)科技股份有限公司股票交易异常波动的询 证函》已收悉，现就公司询证事项回复如下: ...